CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- FinancialsAltman Z-Score -2.26: distress zone
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
809.52MUSDvs all stocks (USD)
Revenue (TTM)
204.56MUSDvs all stocks (USD)
Profit Margin
-33.05%vs Biotechnology peers
Beta
0.6050xvs all stocks
52-Week Change
-3.82%vs all stocks
Market Capitalization
809.52MUSDvs all stocks (USD)
Enterprise Value
630.81MUSDvs all stocks (USD)
Forward P/E
31.50xvs Biotechnology peers
Price to Sales (TTM)
3.96xvs Biotechnology peers
Price to Book (MRQ)
3.71xvs Biotechnology peers
Enterprise to Revenue
3.08xvs Biotechnology peers
Enterprise to EBITDA
-18.13xvs Biotechnology peers
Gross Margin
83.92%vs Biotechnology peers
Profit Margin
-33.05%vs Biotechnology peers
Operating Margin
-22.01%vs Biotechnology peers
Return on Assets (TTM)
-4.11%vs Biotechnology peers
Return on Equity (TTM)
-28.28%vs Biotechnology peers
Revenue (TTM)
204.56MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.3060USDUpdated Sep 27, 2026Quarterly Revenue Growth
17.20%vs Biotechnology peers
Gross Profit (TTM)
119.67MUSDvs all stocks (USD)
EBITDA (TTM)
-34.80MUSDvs all stocks (USD)
Net Income (TTM)
-67.61MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
17.22%vs Biotechnology peers
Operating Cash Flow (TTM)
-114.38MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-78.37MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 27, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
183.88MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
4.75MUSDFY2025 · Dec 31, 2025Gross Profit
179.14MUSDFY2025 · Dec 31, 2025Operating Income
-51.55MUSDvs all stocks (USD)
Pre-tax Income
-83.50MUSDFY2025 · Dec 31, 2025Net Income
-83.50MUSDFY2025 · Dec 31, 2025EBIT
-50.84MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-32.61MUSDFY2025 · Dec 31, 2025Research & Development
71.43MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
159.26MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
18.12MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
32.66MUSDFY2025 · Dec 31, 2025EPS (Basic)
-0.1300USDFY2025 · Dec 31, 2025EPS (Diluted)
-0.1300USDFY2025 · Dec 31, 2025Basic Shares Outstanding
666.66MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
666.66MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-83.50MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-118.43MUSDFY2025 · Dec 31, 2025Free Cash Flow
-118.48MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
79.44MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-83.50MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
1.20MUSDFY2025 · Dec 31, 2025Stock-based Compensation
26.75MUSDFY2025 · Dec 31, 2025Other Non-cash Items
20.02MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-377.00KUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
2.66MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-85.19MUSDFY2025 · Dec 31, 2025Capital Expenditures
-49.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-304.42MUSDFY2025 · Dec 31, 2025Sale of Investments
411.72MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
107.25MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Long-term Debt Payments
0.00USDFY2025 · Dec 31, 2025Net Financing Cash Flow
0.00USDFY2025 · Dec 31, 2025Shares Outstanding
642.47MSharesUpdated Sep 27, 2026Float Shares
556.32MSharesUpdated Sep 27, 2026Shares Short
82.62MSharesUpdated Sep 27, 2026Short Ratio
8.26daysvs all stocks
Short % of Shares Outstanding
12.87%vs all stocks
% Held by Insiders
0.08%vs all stocks
% Held by Institutions
76.63%vs all stocks
Total Cash (MRQ)
300.85MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.4680USDUpdated Sep 27, 2026Total Debt (MRQ)
122.14MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.5587xvs Biotechnology peers
Current Ratio (MRQ)
6.92xvs Biotechnology peers
Book Value per Share (MRQ)
0.3400USDUpdated Sep 27, 2026Total Assets
570.54MUSDvs all stocks (USD)
Total Current Assets
520.27MUSDFY2025 · Dec 31, 2025Total Liabilities
344.67MUSDFY2025 · Dec 31, 2025Total Non-current Assets
50.27MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
233.13MUSDFY2025 · Dec 31, 2025Total Current Liabilities
111.54MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
77.56MUSDFY2025 · Dec 31, 2025Other Short-term Investments
280.36MUSDFY2025 · Dec 31, 2025Accounts Receivable
36.99MUSDFY2025 · Dec 31, 2025Inventory
116.64MUSDFY2025 · Dec 31, 2025Accounts Payable
11.26MUSDFY2025 · Dec 31, 2025Short-term Debt
1.00MUSDFY2025 · Dec 31, 2025Deferred Revenue
3.49MUSDFY2025 · Dec 31, 2025Other Current Liabilities
17.45MUSDFY2025 · Dec 31, 2025Long-term Debt
120.99MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
112.13MUSDFY2025 · Dec 31, 2025Common Stock (Book)
640.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-1.86BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
225.87MUSDvs all stocks (USD)
52-Week Low
1.04USDUpdated Sep 27, 202652-Week High
2.01USDUpdated Sep 27, 202652-Week Change
-3.82%vs all stocks
Beta
0.6050xvs all stocks
50-Day MA
1.45USDUpdated Sep 27, 2026200-Day MA
1.45USDUpdated Sep 27, 2026Avg 10-Day Volume
10.68MSharesUpdated Sep 27, 2026Avg 30-Day Volume
9.98MSharesUpdated Sep 27, 2026Diluted EPS (TTM)
-0.1100USDUpdated Sep 27, 2026Other Income / Expense
-17.41MUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
Where is this company structurally exposed?
Partial Recovery After Sharp Decline
A weak, thin-volume bounce inside a decline that is still far from recovered.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.84Profit Margin: -0.33
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 6.92Altman Z-Score: -2.26
Financial Health
Altman Z-Score -2.26: distress zoneCritical
Altman Z-Score: -2.26
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
DNA Link Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Jiangsu Jibeier Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Chunlizhengda Medical Instruments Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shandong Keyuan Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Lexicon Pharmaceuticals, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Luoxin Pharmaceuticals Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Esperion Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jacobio Pharmaceuticals Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
4D Molecular Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
InMode Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Poet Technologies Inc.
2 interpretationsPartial Recovery After Sharp DeclineHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Qingdao Eastsoft Communication Co., Ltd.
1 interpretationPartial Recovery After Sharp Decline
Sunwoda Electronic Co., Ltd.
1 interpretationPartial Recovery After Sharp Decline